EUVIMEDEUVIMED entdecken
Crossref

Maintenance therapy with low dose cyclophosphamide does not increase the risk of second malignancies: The European Pediatric Soft Tissue Sarcoma Study Group RMS2005 study experience

Gianni Bisogno iD, Andrea Ferrari iD, Raquel Dávila Fajardo, Anna Kelsey, Julia Chisholm iD, Raquel Hladun Alvaro, Christine Devalck, Maja Česen, Nadege Corradini, Beatrice Coppadoro, Veronique Minard-Colin iD, Johannes H M Merks

Cancer · 01.11.2026 · 132 (21)

DOI: 10.1002/cncr.70661 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 27.10.2026. Verfasst von Gianni Bisogno und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Women's and Children's Health, University of Padua, Padua, Italy. Hauptthemen laut MEDLINE: Neoplasms, Second Primary, Cyclophosphamide, Rhabdomyosarcoma, Maintenance Chemotherapy. Die Arbeit nennt 16 Literaturangaben. Gefördert von: Fondazione Città della Speranza, Alice's Arc, United Kingdom.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Survivors of childhood rhabdomyosarcoma (RMS) are at increased risk of second malignant neoplasms (SMNs), influenced by treatment type and genetic predisposition. Recently, the addition of maintenance chemotherapy with low‐dose cyclophosphamide and vinorelbine has improved survival outcomes for patients with high‐risk disease. However, the potential SMN risk from increased cumulative alkylating agent exposure remains unclear.

Methods

The authors analyzed 1633 patients enrolled in the European RMS 2005 trial. Cumulative incidence of SMN was estimated using competing risk methodology. Outcomes were compared between patients who did and did not receive maintenance chemotherapy.

Results

After a median follow‐up of 9.3 years (range, 0.6–17.7), 27 patients (1.7%) developed a SMN. Eight had a known cancer predisposition syndrome: Li‐Fraumeni syndrome (LFS) in six patients and neurofibromatosis type 1 (NF1) in two patients. Osteosarcoma was the most frequent SMN ( n = 6), followed by low‐grade glioma ( n = 3), hematological malignancies ( n = 3), and undifferentiated sarcoma ( n = 2). Twenty of 27 patients with SMN received radiotherapy before developing an SMN, including eight who’s SMN arose within a previously irradiated field. Three of these eight patients had LFS. The 8‐year cumulative incidence of SMN in the entire cohort was 1.3% (95% CI, 0.8–2.0). SMNs occurred in 17 of 1081 patients without maintenance therapy (1.6%) and in nine of 486 patients who received maintenance therapy (1.9%; p = .75).

Conclusion

Maintenance chemotherapy was not associated with increased SMN risk. Genetic predisposition was a major contributor to SMN development, supporting risk‐adapted survivorship care. Longer follow‐up is required to evaluate late‐occurring SMNs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasms, Second PrimaryCyclophosphamideRhabdomyosarcomaMaintenance ChemotherapyAntineoplastic Agents, AlkylatingHumansChildChild, PreschoolFemaleAdolescentInfantMaleAntineoplastic Combined Chemotherapy ProtocolsIncidenceFollow-Up Studies

Stichwörter der Autor:innen

cancer predisposing syndromemaintenance chemotherapyrhabdomyosarcomasecond malignancy

Substanzen

CyclophosphamideAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Department of Women's and Children's Health, University of Padua, Padua, Italy.
  • Pediatric Hematology Oncology Division, University Hospital of Padua, Padua, Italy.
  • Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.
  • Department of Radiation Oncology, University Medical Center, Utrecht, the Netherlands.
  • Department of Paediatric Pathology, Royal Manchester Childrens Hospital, University Foundation Trust, Manchester, UK.

ORCID-Profile: Gianni Bisogno, Andrea Ferrari, Julia Chisholm, Veronique Minard-Colin

Förderung

  • Fondazione Città della Speranza
  • Alice's Arc, United Kingdom

Zitieren

APA

Bisogno, G., Ferrari, A., Fajardo, R. D., Kelsey, A., Chisholm, J., Alvaro, R. H., Devalck, C., Česen, M., Corradini, N., Coppadoro, B., Minard-Colin, V., & Merks, J. H. M. (2026). Maintenance therapy with low dose cyclophosphamide does not increase the risk of second malignancies: The European Pediatric Soft Tissue Sarcoma Study Group RMS2005 study experience. Cancer, 132(21). https://doi.org/10.1002/cncr.70661

Vancouver

Bisogno G, Ferrari A, Fajardo RD, Kelsey A, Chisholm J, Alvaro RH, et al. Maintenance therapy with low dose cyclophosphamide does not increase the risk of second malignancies: The European Pediatric Soft Tissue Sarcoma Study Group RMS2005 study experience. Cancer. 2026;132(21). doi:10.1002/cncr.70661

BibTeX
@article{Bisogno2026,
  author = {Bisogno, Gianni and Ferrari, Andrea and Fajardo, Raquel Dávila and Kelsey, Anna and Chisholm, Julia and Alvaro, Raquel Hladun and Devalck, Christine and Česen, Maja and Corradini, Nadege and Coppadoro, Beatrice and Minard-Colin, Veronique and Merks, Johannes H M},
  title = {Maintenance therapy with low dose cyclophosphamide does not increase the risk of second malignancies: The European Pediatric Soft Tissue Sarcoma Study Group RMS2005 study experience},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {21},
  doi = {10.1002/cncr.70661}
}
Kostenlos starten →